s
s
s
Develop highly selective and sensitive PK and ADA assays for the immune checkpoint inhibitor drug pembrolizumab (Keytruda) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Pembrolizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Pembrolizumab Inhibitory Type 1 |
HCA296 |
AbD30689 |
Fab-FH1 |
0.6 |
PK bridging ELISA |
|
HCA297 |
AbD30685_hIgG1 |
hIgG1 HRP |
5 |
PK bridging ELISA ADA control |
||
HCA298 |
AbD30689_hIgG1 |
hIgG1 |
0.6 |
ADA control |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Type 1 anti-pembrolizumab antibodies inhibit the binding of the drug pembrolizumab to its target, programmed cell death 1 (PD-1). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in two affinities, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Fig. 1. Pembrolizumab PK bridging ELISA using antibodies HCA296 and HCA297P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Pembrolizumab ADA bridging ELISA using antibody HCA297.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.